← Back to Search

Intervention Arm for Chronic Kidney Disease (Kidney-CHAMP Trial)

N/A

Waitlist Available

Led By Khaled Abdel-Kader, MD

Research Sponsored by University of Pittsburgh

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up time to event analysis - until primary outcome or a competing event (death, medication management without dialysis, being moved to hospice care) was achieved or until the end of intervention period (max 39 months). cumulative % at 24 months reported

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a computerized system that helps doctors manage and improve care for patients with high-risk Chronic Kidney Disease. The system provides important health information and guidelines to ensure patients receive the best possible care. It aims to improve blood pressure control, use of specific medications, and avoid harmful drugs, ultimately slowing down CKD progression.

Eligible Conditions

Chronic Kidney Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ time to event analysis - until primary outcome or a competing event (death, medication management without dialysis, being moved to hospice care) was achieved or until the end of intervention period (max 39 months). cumulative % at 24 months reported

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~time to event analysis - until primary outcome or a competing event (death, medication management without dialysis, being moved to hospice care) was achieved or until the end of intervention period (max 39 months). cumulative % at 24 months reported

This trial's timeline: 3 weeks for screening, Varies for treatment, and time to event analysis - until primary outcome or a competing event (death, medication management without dialysis, being moved to hospice care) was achieved or until the end of intervention period (max 39 months). cumulative % at 24 months reported for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Renal Failure Event Defined as Greater Than or Equal to 40% Decline in Estimated Glomerular Filtration Rate (eGFR) or Occurrence of End Stage Renal Disease (ESRD)

Secondary study objectives

Hypertension (HTN) Control Outcome

Medication Safety: Gemfibrozil Exposure Days

Medication Safety: Glyburide Exposure Days Per Year

+3 more

Other study objectives

Subgroup Analysis Hypertension (HTN) Control (Outcome 2) in Participants With Uncontrolled BP at Baseline (i.e., BP >130/80 at Baseline).

Subgroup Analysis: Use of Renin-Angiotensin-Aldosterone System Inhibitors (RAASi) (Outcome 3) in Participants Who Are Baseline Non-users of RAASi

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention ArmExperimental Treatment1 Intervention

Patients will receive a care bundle

Group II: Usual careActive Control1 Intervention

Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).

Do I qualify?Apply below to find out